Insmed Shelves Brinsupri for Hidradenitis Suppurativa After Phase 2b Failure on April 08, 2026 Brinsupri CEDAR study Drug Development Hidradenitis Suppurativa Insmed +
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway in Skin Diseases on April 01, 2026 2026 AAD Alumis Dermatitis, Atopic Dermatomyositis Hidradenitis Suppurativa Incyte Psoriasis Roivant sanofi +
MoonLake revives FDA push on January 13, 2026 Biological Factors Blackfoot language Hidradenitis Suppurativa Hong Kong immunotherapeutics License Application MoonLake sonelokimab Type B meeting United States Food and Drug Administration +
MoonLake revives FDA push on January 12, 2026 Biological Factors Blackfoot language Hidradenitis Suppurativa Hong Kong immunotherapeutics License Application MoonLake sonelokimab Type B meeting United States Food and Drug Administration +
MoonLake revives FDA push on January 12, 2026 Biological Factors Blackfoot language Hidradenitis Suppurativa Hong Kong immunotherapeutics License Application MoonLake sonelokimab Type B meeting United States Food and Drug Administration +
MoonLake revives FDA push on January 09, 2026 Biological Factors Blackfoot language Hidradenitis Suppurativa Hong Kong immunotherapeutics License Application MoonLake sonelokimab Type B meeting United States Food and Drug Administration +
MoonLake revives FDA push on January 09, 2026 Biological Factors Blackfoot language Hidradenitis Suppurativa Hong Kong immunotherapeutics License Application MoonLake sonelokimab Type B meeting United States Food and Drug Administration +
MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies on September 29, 2025 Bimzelx Clinical Trials Cosentyx drug approval outlook drug market Hidradenitis Suppurativa inhibitors Interleukin-17 MoonLake Immunotherapeutics Placebos Response process sonelokimab +
Otsuka Inks $613M Deal for Cantargia's Autoimmune Antibodies on July 16, 2025 Autoimmune Diseases CAN10 Cantargia global commercialization Hidradenitis Suppurativa IL1RAP antibodies milestone payments Otsuka Pharmaceutical Systemic Scleroderma +